Literature DB >> 8792853

Expression and interconversion of neuron-specific enolase in patient sera and extracts from small-cell lung cancer cells.

E Paus1, A T Myklebust.   

Abstract

The isoforms of gamma-enolase were characterized in serum from patients with small-cell lung cancer (SCLC) and in extracts from SCLC cell lines and malignant melanoma tumor tissue. Large variations in the expression of the 3 gamma-isoforms of enolase were observed. These forms probably represent the homodimeric gamma gamma-enolase, the heterodimeric alpha gamma-enolase and the monomeric forms of gamma-enolase. Only the dimeric forms are enzymatically active. The predominant gamma-enolase in the cell lines is the heterodimeric alpha gamma-enolase. The SCLC cell lines can be divided into two groups: one with negligible gamma gamma-enolase expression and considerable amounts of the nonneuronal alpha alpha-enolase and a second group with a large fraction of gamma gamma-enolase concomitant with a low expression of alpha-enolase. Similar patterns are observed in tissue extracts from malignant melanoma. When changing buffer conditions by increasing the ionic strength and decreasing the Mg2+ concentration, interconversions between the isozymes occur. In contrast to the predominant alpha gamma-enolase in extracts from cell lines, the multiple forms of gamma-enolase in serum might be caused by a subunit exchange facilitated by the low Mg2+ concentration in plasma. However, there seems to be a stable equilibrium between the isoforms in undiluted patient serum. The induction of subunit exchange by perturbation in ionic strength and/or Mg2+ concentration indicates a need for caution when choosing diluents for use in assays for neuron-specific enolase.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8792853     DOI: 10.1159/000217989

Source DB:  PubMed          Journal:  Tumour Biol        ISSN: 1010-4283


  2 in total

1.  TD-12 workshop report: characterization of monoclonal antibodies to neuron-specific enolase.

Authors:  Elisabeth Paus; Klaus Hirzel; Maria Lidqvist; Matti Höyhtyä; David J Warren
Journal:  Tumour Biol       Date:  2011-05-14

2.  Gene expression deregulation by KRAS G12D and G12V in a BRAF V600E context.

Authors:  Massimiliano Monticone; Emanuela Biollo; Massimo Maffei; Alessandra Donadini; Francesco Romeo; Clelia Tiziana Storlazzi; Walter Giaretti; Patrizio Castagnola
Journal:  Mol Cancer       Date:  2008-12-16       Impact factor: 27.401

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.